Evaluation of Coagulopathy in Critically Ill COVID-19 Patients.
Evaluation of Coagulopathy in Critically Ill COVID-19 Patients.
Novel coronavirus disease 19 (COVID-19) is caused by severe acute respiratory syndrome
 coronavirus 2 (SARS-CoV-2), this pneumonia was first emerged in December 2019 in Wuhan, China
 and rapidly spread around the world .

 Coagulopathy is one of the most significant prognostic factors in patients with COVID-19 and
 is associated with increased mortality and admission to critical care. Most observed
 coagulopathy in patients hospitalized with COVID-19 (COVID-19-associated coagulopathy) is
 characterized by increased D-dimer and fibrinogen levels. 71% of patients who did not survive
 hospitalization reported to have developed disseminated intravascular coagulation
Inclusion Criteria:

 -  COVID 19 critically ill patients

 Exclusion Criteria:

 -  any critical illness not related to COVID 19